Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 4:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 6,602 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Acne
Interventions: IDP 121 Lotion, IDP-121 Vehicle Lotion; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 9 Years and older
Enrollment: 820 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 34
States / cities: Glendale, Arizona • Rogers, Arkansas • Anaheim, California + 27 more

Conditions: Primary Hyperoxaluria
Interventions: Oxalobacter formigenes, Placebo; Biological · Drug
Lead sponsor: OxThera; Industry
Eligibility: 2 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Nocturia
Interventions: Desmopressin, Placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 41
States / cities: Huntsville, Alabama • Scottsdale, Arkansas • Foothill Ranch, California + 36 more

Conditions: Migraine Disorders
Interventions: LY2951742, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Cypress, California

Conditions: Thalassemia Major
Interventions: DST-0509, Jadenu, Exjade; Drug
Lead sponsor: DisperSol Technologies, LLC; Industry
Eligibility: 8 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Menorrhagia
Interventions: Naproxen, Placebo; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Healthy, Alzheimer's Disease, Mild Cognitive Impairment
Interventions: LY2599666, Solanezumab, Placebo SC, Placebo IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 20 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Glendale, California • Marlton, New Jersey • Salt Lake City, Utah

Conditions: Type 2 Diabetes Mellitus
Interventions: Tesaglitazar 0.5, Insulin at least 30 units/day; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tuscson, Arizona + 68 more

Conditions: Post-stroke Spasticity of the Upper Limb
Interventions: IncobotulinumtoxinA (400 Units), Placebo Comparator; Drug
Lead sponsor: Merz Pharmaceuticals GmbH; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Downey, California • Fountain Valley, California • Miami, Florida + 10 more

Conditions: Asthma
Interventions: FP 100, GSK2190915 100, GSK2190915 300, montelukast, placebo, FP/SAL 100/50; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 32
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 28 more

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Palbociclib, Carboplatin; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 3
States / cities: Indianapolis, Indiana • Ann Arbor, Michigan • Nashville, Tennessee

Conditions: Acne Vulgaris
Interventions: Adapalene and Benzoyl Peroxide Topical Gel, Epiduo Topical Product, Placebo; Drug
Lead sponsor: Padagis LLC; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 825 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Small Cell Lung Cancer
Interventions: APG-1252, Paclitaxel; Drug
Lead sponsor: Ascentage Pharma Group Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Plantation, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more

Conditions: Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
Interventions: rigosertib sodium; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 14
States / cities: Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more

Conditions: Type 2 Diabetes
Interventions: ITCA 650, ITCA placebo; Drug · Other
Lead sponsor: Intarcia Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 121
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Huntsville, Alabama + 102 more

Conditions: Healthy Subjects, Chronic Conditions, Multiple
Interventions: Neteera 130H; Device
Lead sponsor: Neteera Technologies Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Millcreek, Utah

Conditions: Non Small Cell Lung Cancer, Lung Cancer
Interventions: Vandetanib, Pemetrexed; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2023
U.S. locations: 23
States / cities: Casa Grande, Arizona • Chandler, Arizona • Farmington, Connecticut + 20 more

Conditions: Neovascular Age-related Macular Degeneration
Interventions: ADVM-022; Genetic
Lead sponsor: Adverum Biotechnologies, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 34
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 30 more

Conditions: Metastatic Melanoma
Interventions: Obatoclax Mesylate, Temozolomide; Drug
Lead sponsor: Gemin X; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Oropharynx Cancer
Interventions: Carboplatin, Radiation Therapy, Paclitaxel; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Cushings Disease, Cushing Disease
Interventions: LCI699; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Cleveland, Ohio + 1 more

Conditions: Breast Cancer, Reconstructive Breast Surgery
Interventions: OxyGenesys Dissolved Oxygen Dressing, Standard Gauze Dressing; Device
Lead sponsor: Halyard Health; Industry
Eligibility: 21 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 7
States / cities: Chicago, Illinois • St Louis, Missouri • Great Neck, New York + 3 more

Conditions: Stargardt's Macular Dystrophy
Interventions: MA09-hRPE; Biological
Lead sponsor: Astellas Institute for Regenerative Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 3
States / cities: Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Copper Cu 64 PSMA I&T; Drug
Lead sponsor: Curium US LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 43
States / cities: Homewood, Alabama • Little Rock, Arkansas • Fullerton, California + 35 more

Search by objective public record fields.

Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Phase 2/3 Oxabact Study

Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

A Study of LY2951742 in Healthy Japanese and Caucasian Participants

Pilot Study to Assess the Safety, PK and Iron Chelating Activity of DST-0509 (Deferasirox) in Thalassemia Patients Refractory to Chelation

Copper IUD Treatment Observation Study

A Study of LY2599666 in Healthy Participants and Participants With Mild Cognitive Impairment or Alzheimer's Disease (AD)

GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke

Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

Phase II Trial Evaluating the Efficacy of Palbociclib in Combination With Carboplatin for the Treatment of Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face

Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

Heart Rate and Respiratory Rate Measurements by a Novel, Radar-based Device

Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

Safety and Efficacy of LCI699 in Cushing's Disease Patients

Using A Dissolved Oxygen Enriched Dressing in Nipple-sparing Mastectomy

Long Term Follow Up of Sub-retinal Transplantation of hESC Derived RPE Cells in Stargardt Macular Dystrophy Patients

Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer